This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ipca Laboratories Limited. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: The Innovative Mind of Sanjay Govind Barve
Introduction
Sanjay Govind Barve is an esteemed inventor based in Maharashtra, India. With a keen focus on pharmaceuticals, he has contributed to the advancement of medical science through his innovative work. His notable invention involves an improved industrial process in the manufacturing of a vital drug, showcasing his expertise in chemical processes.
Latest Patents
Sanjay holds a patent for his process titled "Industrial process for preparation of Clopidogrel hydrogen sulphate." This innovative method begins with 2-(2-thienyl) ethylamine and eliminates the need to isolate an unstable intermediate, such as 2-(2-thienyl) ethyl formimine. Instead, it employs a one-pot cyclization method, yielding 4, 5, 6, 7-tetrahydrothieno (3,2-c) pyridine. Furthermore, this patent outlines a way to resolve racemic Clopidogrel into its optical antipodes and convert dextroclopidogrel base into its known polymorphs, demonstrating both novelty and utility in pharmaceutical manufacturing.
Career Highlights
Currently, Sanjay is associated with Ipca Laboratories Limited, where his innovative contributions play a crucial role in the company’s research and development efforts. His work not only enhances the production process of critical pharmaceuticals but also has significant implications for drug efficacy and safety.
Collaborations
Sanjay collaborates with talented professionals like Ashok Kumar and Ketan Dhansukhlal Vyas. Their combined expertise fosters an environment of innovation and progress in pharmaceutical research and development, further advancing the field.
Conclusion
Sanjay Govind Barve exemplifies the spirit of innovation in the pharmaceutical industry. His significant contributions through his patent for the industrial process of manufacturing Clopidogrel hydrogen sulphate underline his commitment to improving pharmaceutical practices. As he continues to work with dedicated colleagues at Ipca Laboratories Limited, the potential for further advancements in pharmaceuticals remains promising.